Introduction to the pharmacoeconomics of diabetes care;Wstȩp do farmakoekonomiki cukrzycy

Diabetologia Polska

Volumn 10, Issue 4, 2003, Pages 429-433

  Kawalec, Pawelł ^a,b   Pilc, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b NONE   (Poland)

Author keywords

Diabetes treatment; Pharmacoeconomics

Indexed keywords

COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; PATIENT CARE; POLAND; REVIEW;

EID: 1642338138     PISSN: 12334723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Bootman J.I., Townsend R. Principles of Pharmacoeconomics. Harvey Witney books Company Cincinnati 1999
2. Spławiński J. Receptariusz szpitalny. Unimed 1999
3. Orlewska E. Podstawy Farmakoekonomiki. Unimed Warszawa 1999
4. Orlewska E. "Wytyczne dla dobrej praktyki farmaceutycznej." Zdrowie i Zarza̧dzanie. Tom I, nr 4/1999.
5. Herold G. Medycyna wewnȩtrzna. Repetytorium. Wydawnictwo Lekarskie PZWL 1996
6. Grzywa M., Sobel A. Niektóre kierunki badań w epidemiologii cukczycy typu 1 insulionozależnej (IDDM). Pol. Arch. Med. Wewn., 1994, 329, 329-338.
7. Jarosz-Chobot P. Czy mamy już epidemiȩ cukrzycy typu 1? Stużba zdrowia, 2001, 32-35, 25-26.
8. A report of the Diabetes Health Economics Study Group. The Economics of Diabetes and Diabetes Care International Diabetes Federation and World Health Organization (Division of non-communicable diseases) 1997.
9. Economic consequences of Diabetes Mellitus in the U.S. in 1997 American Diabetes Association Diabetes Care, 1997, 21, 296-309.
10. Massi-Benedetti M. CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia, 2002, 45, S1-4.
11. DCCT (the Diabetes Control and Complications Trial). N. Eng. J. Med., 329, 1993.